Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher Crane

Showing results (61-70 of 67) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 67 results.
The New England Journal of Medicine|June 6, 2022
PD-1 Blockade in Mismatch Repair-Deficient, Locally Advanced Rectal CancerAndrea Cercek, Melissa Lumish, Jenna Sinopoli, et al.
Journal of Pharmacy & Pharmaceutical Sciences : a Publication of the Canadian Society for Pharmaceutical Sciences, Societe Canadienne Des Sciences Pharmaceutiques|October 17, 2022
A Survey of the Criteria Used for the Selection of Alternative Comparator Products by Participating Regulators and Organizations of the International Pharmaceutical Regulators ProgrammeAndrew Tam, Alfredo Garcia-Arieta, Ivana Abalos, et al.
Journal of Pharmacy & Pharmaceutical Sciences : a Publication of the Canadian Society for Pharmaceutical Sciences, Societe Canadienne Des Sciences Pharmaceutiques|October 27, 2021
Requirements for Additional Strength Biowaivers for Modified Release Solid Oral Dosage Forms in International Pharmaceutical Regulators Programme Participating Regulators and Organisations: Differences and CommonalitiesMatthias Shona Roost, Henrike Potthast, Chantal Walther, et al.
Journal of Pharmacy & Pharmaceutical Sciences : a Publication of the Canadian Society for Pharmaceutical Sciences, Societe Canadienne Des Sciences Pharmaceutiques|April 5, 2024
The bioequivalence study design recommendations for immediate-release solid oral dosage forms in the international pharmaceutical regulators programme participating regulators and organisations: differences and commonalitiesEduardo Agostinho Freitas Fernandes, Joy van Oudtshoorn, Andrew Tam, et al.
JAMA Oncology|January 11, 2019
Assessment of a Watch-and-Wait Strategy for Rectal Cancer in Patients With a Complete Response After Neoadjuvant TherapyJ Joshua Smith, Paul Strombom, Oliver S Chow, et al.
Journal of the National Cancer Institute|October 26, 2024
Adjuvant modified FOLFIRINOX for resected pancreatic adenocarcinoma: clinical insights and genomic features from a large contemporary cohortFergus Keane, Catherine O'Connor, Drew Moss, et al.
Journal of Pharmacy & Pharmaceutical Sciences : a Publication of the Canadian Society for Pharmaceutical Sciences, Societe Canadienne Des Sciences Pharmaceutiques|November 5, 2025
A survey of regulatory recommendations for waivers of <i>in vivo</i> bioequivalence studies of generic products for certain dosage forms by participating regulators and organisations of the International Pharmaceutical Regulators Programme. Part 2Alfredo García-Arieta, Andrew Tam, Florencia Tiseyra, et al.
Pageof 7

Showing results (61-70 of 67) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 67 results.
The New England Journal of Medicine|June 6, 2022
PD-1 Blockade in Mismatch Repair-Deficient, Locally Advanced Rectal CancerAndrea Cercek, Melissa Lumish, Jenna Sinopoli, et al.
Journal of Pharmacy & Pharmaceutical Sciences : a Publication of the Canadian Society for Pharmaceutical Sciences, Societe Canadienne Des Sciences Pharmaceutiques|October 17, 2022
A Survey of the Criteria Used for the Selection of Alternative Comparator Products by Participating Regulators and Organizations of the International Pharmaceutical Regulators ProgrammeAndrew Tam, Alfredo Garcia-Arieta, Ivana Abalos, et al.
Journal of Pharmacy & Pharmaceutical Sciences : a Publication of the Canadian Society for Pharmaceutical Sciences, Societe Canadienne Des Sciences Pharmaceutiques|October 27, 2021
Requirements for Additional Strength Biowaivers for Modified Release Solid Oral Dosage Forms in International Pharmaceutical Regulators Programme Participating Regulators and Organisations: Differences and CommonalitiesMatthias Shona Roost, Henrike Potthast, Chantal Walther, et al.
Journal of Pharmacy & Pharmaceutical Sciences : a Publication of the Canadian Society for Pharmaceutical Sciences, Societe Canadienne Des Sciences Pharmaceutiques|April 5, 2024
The bioequivalence study design recommendations for immediate-release solid oral dosage forms in the international pharmaceutical regulators programme participating regulators and organisations: differences and commonalitiesEduardo Agostinho Freitas Fernandes, Joy van Oudtshoorn, Andrew Tam, et al.
JAMA Oncology|January 11, 2019
Assessment of a Watch-and-Wait Strategy for Rectal Cancer in Patients With a Complete Response After Neoadjuvant TherapyJ Joshua Smith, Paul Strombom, Oliver S Chow, et al.
Journal of the National Cancer Institute|October 26, 2024
Adjuvant modified FOLFIRINOX for resected pancreatic adenocarcinoma: clinical insights and genomic features from a large contemporary cohortFergus Keane, Catherine O'Connor, Drew Moss, et al.
Journal of Pharmacy & Pharmaceutical Sciences : a Publication of the Canadian Society for Pharmaceutical Sciences, Societe Canadienne Des Sciences Pharmaceutiques|November 5, 2025
A survey of regulatory recommendations for waivers of <i>in vivo</i> bioequivalence studies of generic products for certain dosage forms by participating regulators and organisations of the International Pharmaceutical Regulators Programme. Part 2Alfredo García-Arieta, Andrew Tam, Florencia Tiseyra, et al.
Pageof 7